Firefly Bio

Firefly Bio has developed a novel platform for treating cancer using Degradable Antibody Conjugates (DAC). This platform enables highly specific delivery of payloads to target tissues. Firefly Bio, headquartered in South San Francisco, is backed by a leading syndicate including founding investors Versant Ventures, MPM BioCapital, Decheng, and Eli Lilly and Company.